|1.||Ropo, Auli: 10 articles (01/2015 - 08/2007)|
|2.||Holló, Gábor: 4 articles (04/2015 - 08/2014)|
|3.||Pfeiffer, Norbert: 4 articles (12/2014 - 05/2010)|
|4.||Uusitalo, Hannu: 4 articles (12/2014 - 02/2010)|
|5.||Kimmich, Friedemann: 4 articles (01/2013 - 08/2010)|
|6.||Traverso, Carlo E: 3 articles (12/2014 - 02/2010)|
|7.||Hommer, Anton: 3 articles (08/2014 - 08/2010)|
|8.||Aihara, Makoto: 3 articles (03/2014 - 01/2010)|
|9.||Nucci, Paolo: 3 articles (01/2014 - 01/2012)|
|10.||Sacchi, Matteo: 3 articles (01/2014 - 01/2012)|
06/01/2013 - "Topical tafluprost increased MBR in the optic nerve head and significantly reduced IOP, effects that may represent beneficial treatment for glaucoma patients with a myopic disc type."
11/01/2013 - "The study confirmed the efficacy of preservative-free Tafluprost in reducing IOP, and underlined the drug's safety in naïve glaucoma patients with regard to corneal status. "
11/01/2013 - "Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: a single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group."
08/01/2013 - "Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study."
01/01/2015 - "Tafluprost had a greater effect than DTFC; thus, this drug is recommended for patients at risk of glaucoma progression, due to the high OPA caused by large fluctuations in IOP. "
|2.||Ocular Hypertension (Glaucoma, Suspect)
09/01/2011 - "Since its introduction in 2008, initial studies have demonstrated that preserved and preservative-free tafluprost formulations have proven efficacy and safety in the treatment of glaucoma and ocular hypertension. "
02/01/2010 - "Tafluprost is a new effective and well-tolerated treatment for glaucoma and ocular hypertension."
09/01/2011 - "The objective of this review is to evaluate the safety and efficacy of tafluprost, a fluoroprostaglandin receptor analog, for reduction of intraocular pressure in open angle glaucoma and ocular hypertension. "
04/01/2014 - "Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety."
01/01/2014 - "Nonetheless, most clinical studies have demonstrated that not only preservative-free tafluprost but also BAK-preserved tafluprost is well tolerated and safe in patients with glaucoma and ocular hypertension. "
|3.||Open-Angle Glaucoma (Glaucoma, Open Angle)
01/01/2013 - "These studies suggested that application of tafluprost once daily is a safe and effective treatment for patients with open angle glaucoma."
09/01/2013 - "To evaluate the effect of tafluprost on the central corneal thickness (CCT) in patients with primary open-angle glaucoma (POAG). "
09/01/2013 - "Effect of tafluprost 0.0015% on central corneal thickness in patients with primary open-angle glaucoma."
01/01/2013 - "Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma."
01/01/2012 - "Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma."
|4.||Low Tension Glaucoma
01/01/2013 - "Tafluprost single-use vials treatment was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%-13.8% in patients with normal-tension glaucoma. "
05/01/2010 - "[Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study]."
01/01/2013 - "Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma."
11/01/2011 - "To evaluate the intraocular pressure (IOP)-reducing effects and safety of 0.0015% tafluprost ophthalmic solution (tafluprost) in normal-tension glaucoma (NTG) patients with an IOP of 16 mmHg or less. "
11/01/2011 - "Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less."
08/01/2015 - "To evaluate the safety and efficacy of benzalkonium chloride (BAK)-optimized tafluprost (with a BAK concentration reduced from 0.01% to 0.001%) in glaucoma patients with existing superficial punctate keratitis (SPK). "
08/01/2015 - "Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients With Existing Superficial Punctate Keratitis."
|5.||Benzalkonium Compounds (Benzalkonium Chloride)
|6.||Ophthalmic Solutions (Eye Drops)
|8.||Synthetic Prostaglandins (Prostaglandin Analogues)
|9.||prostaglandin F2alpha receptor
|10.||Glutamic Acid (Glutamate)